Picture of HALEON logo

HLN HALEON News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

REG - Haleon PLC - Director/PDMR Shareholding

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260324:nRSX9479Xa&default-theme=true

RNS Number : 9479X  Haleon PLC  24 March 2026

 

Haleon plc: Director/PDMR Shareholding

 

24 March 2026: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today
announces notification and public disclosure in accordance with the
requirements of The UK Market Abuse Regulation of Transactions by a Person
Discharging Managerial Responsibilities ("PDMR").

 

This notification sets out the details of the vesting of Haleon share awards
over ordinary shares made to a PDMR in March 2023 under the Haleon Performance
Share Plan and Deferred Annual Bonus Plan and the subsequent sale of ordinary
shares to meet tax liabilities.

 

On 23 March 2026, Brian McNamara, Chief Executive Officer, received the
vesting of awards of Haleon ordinary shares under the Haleon Performance Share
Plan and Deferred Annual Bonus Plan. Vesting under both plans included
dividends accrued.

The award under the Performance Share Plan was conditional on continued
employment and on the satisfaction of the performance conditions over the
performance period ended on 31 December 2025 approved by the Remuneration
Committee, which (after tax on the gross award) must be retained until the
shareholding requirement is met, and in any event for Executive Directors two
years after receipt.

Performance targets and levels of achievement are disclosed in the 2025 Annual
Report and 20-F. The awards are subject to malus and clawback provisions.

 1       Details of the issuer or emission allowance market participant

 a)      Name of the entity                                       Haleon plc

 b)      LEI                                                      549300PSB3WWEODCUP19

 2       Reason for the notification

 a)      Position/status                                          Chief Executive Officer

 b)      Initial notification /Amendment to prior notifications   Initial Notification

 3       Details of the person discharging managerial responsibilities / person closely

       associated ("PCA")

 a)      PDMR/PCA                                                 PDMR

 b)      Name                                                     Brian McNamara

 4       Details of the transaction(s): section to be repeated for (i) each type of

       instrument; (ii) each type of transaction; (iii) each date; and (iv) each
         place where transactions have been conducted

 a)      Description of Instrument                                Share

         Identification code                                      GB00BMX86B70

 b)      Nature of the transaction                                Acquisition of Ordinary Shares in respect of the Haleon plc Performance Share

                                                        Plan.

 c)      Currency, Price(s) and Volume(s)

                                                                                                      Price(s)          Volume(s)
                                                                                                      Nil               1,497,695.24

 d)      Aggregated information

         - Aggregated volume                                      N/A

         - Price

 e)      Date of the transaction                                  23 March 2026

 f)      Place of the transaction                                 Outside a trading venue

 4       Details of the transaction(s): section to be repeated for (i) each type of

       instrument; (ii) each type of transaction; (iii) each date; and (iv) each
         place where transactions have been conducted

 a)      Description of Instrument                                Share

         Identification code                                      GB00BMX86B70

 b)      Nature of the transaction                                Automatic disposal of Ordinary Shares resulting from Haleon plc Performance

                                                        Share Plan vesting to cover tax liabilities.

 c)      Currency, Price(s) and Volume(s)

                                                                                                      Price(s)          Volume(s)
                                                                                                      £3.684419         704,974.22

 d)      Aggregated information

         - Aggregated volume                                      N/A

         - Price

 e)      Date of the transaction                                  23 March 2026

 f)      Place of the transaction                                 London Stock Exchange (XLON) 

 4       Details of the transaction(s): section to be repeated for (i) each type of

       instrument; (ii) each type of transaction; (iii) each date; and (iv) each
         place where transactions have been conducted

 a)      Description of Instrument                                Share

         Identification code                                      GB00BMX86B70

 b)      Nature of the transaction                                Acquisition of Ordinary Shares in respect of the Haleon plc Deferred Annual

                                                        Bonus Plan.

 c)      Currency, Price(s) and Volume(s)

                                                                                                      Price(s)          Volume(s)
                                                                                                      Nil               133,733.56

 d)      Aggregated information

         - Aggregated volume                                      N/A

         - Price

 e)      Date of the transaction                                  23 March 2026

 f)      Place of the transaction                                 Outside a trading venue

 4       Details of the transaction(s): section to be repeated for (i) each type of

       instrument; (ii) each type of transaction; (iii) each date; and (iv) each
         place where transactions have been conducted

 a)      Description of Instrument                                Share

         Identification code                                      GB00BMX86B70

 b)      Nature of the transaction                                Automatic disposal of Ordinary Shares resulting from Haleon plc Deferred

                                                        Annual Bonus Plan vesting to cover tax liabilities.

 c)      Currency, Price(s) and Volume(s)

                                                                                                      Price(s)          Volume(s)
                                                                                                      £3.684419         63,012.31

 d)      Aggregated information

         - Aggregated volume                                      N/A

         - Price

 e)      Date of the transaction                                  23 March 2026

 f)      Place of the transaction                                 London Stock Exchange (XLON) 

 

 

Amanda Mellor

Company Secretary

 

About Haleon

Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better
everyday health. Our people, our brands, our research, our investment and our
innovation are aimed at improving the everyday health of consumers. Our
product portfolio spans six major categories - Oral Health, Vitamins, Minerals
and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and
Therapeutic Skin Health and Other. Our superior brands - such as Advil,
Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and
Voltaren - are trusted by more than one billion consumers and are recommended
by health professionals around the world.

 

For more information, please visit www.haleon.com (http://www.haleon.com/)
.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBSGDXSXDDGLS



            Copyright 2019 Regulatory News Service, all rights reserved

Recent news on HALEON

See all news